Strategic partnership created to develop and
license a new vocal biomarker detection and monitoring capability
for COPD in India
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the
“Company”), a biotherapeutics company, today announces that its
Founded Entity, Sonde Health (“Sonde”), a leading enterprise vocal
biomarker company, has signed a multi-year agreement with Koye
Pharmaceuticals, a specialty pharma organization focused on the
Indian Pharmaceutical market, to develop a new vocal biomarker
detection and monitoring capability for chronic obstructive
pulmonary disease (COPD) in India. This deal represents Sonde’s
first partnership with a pharmaceutical company.
As part of this arrangement, Koye will leverage Sonde’s vocal
biomarker development platform, expanding upon its already existing
respiratory responsive vocal biomarker, to create an entirely novel
vocal biomarker for COPD in India. This will allow Koye to develop
solutions that help track and treat respiratory health in COPD
patients using their voice.
Sonde Health has previously developed and commercialized vocal
biomarker technology to detect and monitor respiratory impairment.
In early 2022, the company partnered with GN Group, a leading
global manufacturer of hearing instruments and audiological
diagnostics equipment and headsets, to create vocal biomarker
technology to detect Mild Cognitive Impairment.
The full text of the announcement from Sonde is as follows:
Sonde Health Inks Multi-Year Partnership
with Koye Pharmaceuticals
Strategic partnership created to develop and
license a new vocal biomarker detection and monitoring capability
for COPD in India
BOSTON – August 24, 2022 -- Sonde Health, a leading
enterprise vocal biomarker company, has signed a multi-year
agreement with Koye Pharmaceuticals, a specialty pharma
organization focused on the Indian Pharmaceutical market, to
develop a new vocal biomarker detection and monitoring capability
for chronic obstructive pulmonary disease (COPD) in India. This
deal represents Sonde’s first partnership with a pharmaceutical
company.
As part of this arrangement, Koye will leverage Sonde’s vocal
biomarker development (VBD) platform, expanding upon its already
existing respiratory responsive vocal biomarker, to create an
entirely novel vocal biomarker for COPD in India. This will allow
Koye to develop solutions that help track and treat respiratory
health in COPD patients using their voice.
“This collaboration marks a major milestone in Sonde Health’s
growth and evolution, and we’re excited to take this step with Koye
Pharmaceuticals,” David Liu, CEO of Sonde Health. “Partnering
directly with pharmaceutical companies allows them to take a more
targeted and engaging approach with prospective patients, aligning
their needs with the most impactful therapeutics. While there’s no
cure for COPD, this new vocal biomarker will allow physicians to
better manage their patients’ symptoms using early monitoring and
constant engagement to ensure those impacted by COPD get on the
right treatment plans early and often.”
COPD, a chronic inflammatory lung disease that creates airflow
blockage and makes it difficult to breathe, is the third leading
cause of death worldwide – causing 3.23 million deaths in 2019,
according to the World Health Organization – and the second highest
cause of death and disability in adjusted life years (DALYs) in
India after heart disease, per the University of Washington’s
Global Burden of Disease study. As of 2018, India had 18% of the
world’s population, but 32% of the COPD cases. COPD was responsible
for 13% of all deaths in India. A worldwide study has estimated
that India’s death rate from COPD during 2019 was 98 per 100,000
population, three times the American rate of 33 and the British
rate of 31. According to the latest figures, India has an estimated
50 million people living with COPD.
“We have been keen on utilizing an accessible platform with
digital biomarkers that will both aid physicians in identifying and
understanding their patients’ conditions better and also make it
easier for patients with chronic respiratory conditions to monitor
their health in the least invasive way possible. This partnership
with Sonde Health is exactly what we were looking for,” said
Preetish Toraskar, Founder and Director at Koye Pharmaceuticals.
“Not only is Sonde at the forefront of vocal biomarker technology,
but their extensive experience in respiratory health will prove
invaluable as we work to get this debilitating condition under
control in India.”
Sonde Health has previously developed and commercialized vocal
biomarker technology to detect and monitor respiratory impairment.
In early 2022, the company partnered with GN Group, a leading
global manufacturer of hearing instruments and audiological
diagnostics equipment and headsets, to create vocal biomarker
technology to detect Mild Cognitive Impairment.
Sonde Health and Koye Pharmaceuticals plan to explore developing
more vocal biomarkers during their multi-year arrangement.
About Sonde Health Sonde Health has developed an
enterprise vocal biomarker platform that enables any company to
either license respiratory or mental fitness monitoring product or
create a novel vocal biomarker product. Sonde scales data
collection, feature development, model creation and clinical
validation in collaboration with its partners and customers.
Leveraging over 1 million voice samples from 80,000+ individuals,
Sonde uses advanced audio signal processing and machine learning to
sense and analyze subtle vocal changes due to changes in a person’s
physiology to provide key insights into health and well-being.
www.sondehealth.com
About Koye Pharmaceuticals Koye Pharmaceuticals Pvt. Ltd.
was founded in 2013 by two experienced professionals of the pharma
industry, Mr. Preetish Toraskar and Mr. Ravindra Shenoy. Since its
foundation, Koye has expanded its operations to run across the
length and breadth of the country aided by their strong
distribution network. Koye today has more than 1250+ qualified
ambassadors who meet up with more than 100,000+ doctors across the
country every month. The company which believes in pursuing
'healthiness' has a strong foothold in different therapeutic
segments that include state-of-the-art products in Specialty
Primary Care, Respiratory, Gynaecology, IVF and Cardio-Diabetic
segments.
About PureTech Health PureTech is a biotherapeutics
company dedicated to changing the treatment paradigm for
devastating diseases. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders.
This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 27
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization, as of the date of PureTech's most recently filed
Annual Report and corresponding Form 6-K. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh
Cautionary Note Regarding Forward-Looking Statements This
press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those statements that relate to our expectations
regarding Sonde’s vocal biomarker development platform and its
monitoring capability for chronic obstructive pulmonary disease,
its ability to potentially develop a new vocal biomarker detection
and monitoring capability for COPD in India, and Sonde’s future
prospects, development plans, and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2021 filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220824005574/en/
PureTech Public Relations
publicrelations@puretechhealth.com
Investor Relations IR@puretechhealth.com
EU Media Ben Atwell, Rob Winder +44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media Nichole Sarkis +1 774 278 8273
nichole@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024